Jani D, Wang Y, Zhou J, Garant MJ, EganJM: Once daily injection of exendin-4 todiabetic mice achieves long-term beneﬁ-cial effects on blood glucose concentra-tions. Diabetologia 42:45–50, 1999 29. Gedulin B, Lawler R, Jodka C, Young A: Amylin inhibits pentagastrin-stimulatedgastric acid secretion: comparison withglucagon-like peptide-1 and exendin-4(Abstract). Diabetes 46 (Suppl. 1):188A, 1997 30. Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, NiijimaA, Uchida K: The hepatic vagal receptionof intraportal GLP-1 is via receptor differ-ent from the pancreatic GLP-1 receptor. J Auton Nerv Syst 80:14–21, 2000 31. American Diabetes Association: Standards of medical care for patients with diabetesmellitus (Position Statement). Diabetes Care 25 (Suppl. 1):S33–S49, 2002 32. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insu-lin sensitivity, and /H9252-cell function in type